Growth Metrics

ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $75.0 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 11.94% to $75.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $307.0 million through Dec 2025, up 18.99% year-over-year, with the annual reading at $307.0 million for FY2025, 18.99% up from the prior year.
  • Change in Acquisitions & Divestments hit $75.0 million in Q4 2025 for ARS Pharmaceuticals, down from $88.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $88.5 million in Q3 2025 to a low of $20.0 million in Q1 2023.
  • Historically, Change in Acquisitions & Divestments has averaged $62.5 million across 3 years, with a median of $62.2 million in 2024.
  • Biggest YoY gain for Change in Acquisitions & Divestments was 175.0% in 2024; the steepest drop was 1.67% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $60.0 million in 2023, then grew by 11.67% to $67.0 million in 2024, then rose by 11.94% to $75.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for SPRY at $75.0 million in Q4 2025, $88.5 million in Q3 2025, and $80.0 million in Q2 2025.